Avista To Acquire BioReliance Corp.

Avista Capital Partners has agreed to acquire BioReliance Corp. from Invitrogen Corp. (Nasdaq: IVGN) for approximately $210 million. BioReliance is a Rockville, Md.-based contract service organization providing biological safety testing, toxicology, viral manufacturing, and laboratory animal diagnostic services to the global pharma market. The transaction is expected to close next quarter. www.avistacap.com www.bioreliance.com